Russell Investments Group Ltd. lowered its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 30.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 15,448 shares of the biotechnology company’s stock after selling 6,686 shares during the period. Russell Investments Group Ltd.’s holdings in CytomX Therapeutics were worth $281,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. FMR LLC increased its stake in shares of CytomX Therapeutics by 0.6% during the second quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock valued at $85,444,000 after buying an additional 34,732 shares during the period. Vanguard Group Inc. increased its stake in shares of CytomX Therapeutics by 12.2% during the second quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock valued at $14,323,000 after buying an additional 100,607 shares during the period. Redmile Group LLC increased its stake in shares of CytomX Therapeutics by 2.4% during the second quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock valued at $10,825,000 after buying an additional 16,500 shares during the period. Numeric Investors LLC purchased a new position in shares of CytomX Therapeutics during the second quarter valued at $9,730,000. Finally, State Street Corp increased its stake in shares of CytomX Therapeutics by 58.8% during the second quarter. State Street Corp now owns 446,315 shares of the biotechnology company’s stock valued at $6,914,000 after buying an additional 165,342 shares during the period. Hedge funds and other institutional investors own 63.13% of the company’s stock.
In other CytomX Therapeutics news, CFO Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $20.00, for a total value of $50,000.00. Following the transaction, the chief financial officer now owns 12,126 shares in the company, valued at $242,520. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frederick W. Gluck sold 5,000 shares of CytomX Therapeutics stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $22.29, for a total value of $111,450.00. The disclosure for this sale can be found here. Insiders sold 54,234 shares of company stock worth $1,120,525 in the last quarter. 4.70% of the stock is owned by insiders.
Several equities analysts have recently commented on the company. BidaskClub upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 15th. Cowen restated an “outperform” rating on shares of CytomX Therapeutics in a research note on Thursday, October 5th. Oppenheimer restated a “hold” rating on shares of CytomX Therapeutics in a research note on Wednesday, October 4th. Wedbush set a $37.00 price target on CytomX Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 4th. Finally, Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research note on Monday, October 23rd. They set an “overweight” rating and a $35.00 price target on the stock. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $32.78.
COPYRIGHT VIOLATION NOTICE: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/01/08/russell-investments-group-ltd-cuts-stake-in-cytomx-therapeutics-inc-ctmx.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.